community download

Presentation: Impact of HPV prophylactic vaccines - vaccine uptake and barriers

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Dr Robert A. Bednarczyk, Epidemiologist, Hubert Department of Global Health, Rollins School of Public Health , Emory University.

The HPV vaccine has been effective in preventing infection with human papillomavirus but not sufficient in other areas of infection prevention. The vaccine is becoming more widely used, for example, since 2008, in the UK the NHS vaccinates all girls aged 12-13. However, globally it is still not as widely used as other vaccines designed for adolescents, the reason for this are unclear: perhaps racial or ethical differences, or maybe the differences in socioeconomic status.

Why not download the full presentation and discover more about the impact of HPV prophylactic vaccines, the vaccine uptake and some barriers:

• Understanding human papillomavirus (HPV) vaccine uptake patterns
• Addressing concerns about the vaccine and safety issues